Aadi bioscience to present at 2022 h.c. wainwright bioconnect virtual conference

Los angeles, jan. 04, 2022 (globe newswire) -- aadi bioscience, inc. (“aadi”), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced that founder, chief executive officer and president, neil desai, ph.d., will present at the h.c. wainwright bioconnect conference, to be held virtually january 10-13, 2022. the presentation will be available beginning on monday, january 10, 2022 at 7:00 a.m. et.
AADI Ratings Summary
AADI Quant Ranking